Return to flight with multiple sclerosis: aeromedical considerations
Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents...
Gespeichert in:
Veröffentlicht in: | Aviation, space, and environmental medicine space, and environmental medicine, 2011-01, Vol.82 (1), p.61-64 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 64 |
---|---|
container_issue | 1 |
container_start_page | 61 |
container_title | Aviation, space, and environmental medicine |
container_volume | 82 |
creator | Zinger, Hasya Grossman, Alon Assa, Amit Barel, Oshri Barenboim, Erez Levite, Ronen |
description | Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents can minimize relapse rate and slow disease progression. Yet most patients suffer relapses and progression despite use of these agents. Several of the manifestations of MS may cause overall decrease in the performance of the aviator. These include cognitive impairment, fatigue, and depression. Episodes of spasms, dysarthria, ataxia, parasthesias, diplopia, and hemiplegia, as well as drug side effects may also affect flight. Seizures and episodes of vertigo may occur suddenly and result in in-flight incapacitation. We present our experience with two aviators with definite MS and a navigator with probable MS. The various manifestations of MS are specifically addressed with an emphasis on the aeromedical implications. |
doi_str_mv | 10.3357/ASEM.2774.2011 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_843416303</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>843416303</sourcerecordid><originalsourceid>FETCH-LOGICAL-c249t-18901e0a4ebb89ea80d7cbc4a86c396896be83291fa271c9e4a907a11383c5383</originalsourceid><addsrcrecordid>eNo9kEtPwzAQhH0A0VK4ckS5cUpYP5LY3KpSHlIREo-z5bgbauQ0JXaE-PckauGyO4fZ0c5HyAWFjPO8vJ6_Lp8yVpYiY0DpEZkCqDwt8oJNyGkInwDABYMTMmGU8ZyCmpLbF4x9t01im9TefWxi8u3iJml6H93OYxKsx64NLtwkZhANrp01PrHtNrg1dia6QZ2R49r4gOeHPSPvd8u3xUO6er5_XMxXqWVCxZRKBRTBCKwqqdBIWJe2ssLIwnJVSFVUKDlTtDaspFahMApKQymX3ObDmJGrfe6ua796DFE3Llj03myx7YOWggtacOCDM9s77fB86LDWu841pvvRFPQIS4-w9AhLj7CGg8tDdF8NJf_tf6T4L8ctZuA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>843416303</pqid></control><display><type>article</type><title>Return to flight with multiple sclerosis: aeromedical considerations</title><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><creator>Zinger, Hasya ; Grossman, Alon ; Assa, Amit ; Barel, Oshri ; Barenboim, Erez ; Levite, Ronen</creator><creatorcontrib>Zinger, Hasya ; Grossman, Alon ; Assa, Amit ; Barel, Oshri ; Barenboim, Erez ; Levite, Ronen</creatorcontrib><description>Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents can minimize relapse rate and slow disease progression. Yet most patients suffer relapses and progression despite use of these agents. Several of the manifestations of MS may cause overall decrease in the performance of the aviator. These include cognitive impairment, fatigue, and depression. Episodes of spasms, dysarthria, ataxia, parasthesias, diplopia, and hemiplegia, as well as drug side effects may also affect flight. Seizures and episodes of vertigo may occur suddenly and result in in-flight incapacitation. We present our experience with two aviators with definite MS and a navigator with probable MS. The various manifestations of MS are specifically addressed with an emphasis on the aeromedical implications.</description><identifier>ISSN: 0095-6562</identifier><identifier>DOI: 10.3357/ASEM.2774.2011</identifier><identifier>PMID: 21235109</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aerospace Medicine ; Executive Function ; Humans ; Israel ; Male ; Military Personnel ; Multiple Sclerosis - complications ; Multiple Sclerosis - drug therapy ; Neurologic Examination ; Optic Neuritis - drug therapy ; Optic Neuritis - etiology ; Paresthesia - drug therapy ; Paresthesia - etiology ; Space life sciences ; Vision Disorders - drug therapy ; Vision Disorders - etiology ; Work Capacity Evaluation</subject><ispartof>Aviation, space, and environmental medicine, 2011-01, Vol.82 (1), p.61-64</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>214,314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21235109$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zinger, Hasya</creatorcontrib><creatorcontrib>Grossman, Alon</creatorcontrib><creatorcontrib>Assa, Amit</creatorcontrib><creatorcontrib>Barel, Oshri</creatorcontrib><creatorcontrib>Barenboim, Erez</creatorcontrib><creatorcontrib>Levite, Ronen</creatorcontrib><title>Return to flight with multiple sclerosis: aeromedical considerations</title><title>Aviation, space, and environmental medicine</title><addtitle>Aviat Space Environ Med</addtitle><description>Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents can minimize relapse rate and slow disease progression. Yet most patients suffer relapses and progression despite use of these agents. Several of the manifestations of MS may cause overall decrease in the performance of the aviator. These include cognitive impairment, fatigue, and depression. Episodes of spasms, dysarthria, ataxia, parasthesias, diplopia, and hemiplegia, as well as drug side effects may also affect flight. Seizures and episodes of vertigo may occur suddenly and result in in-flight incapacitation. We present our experience with two aviators with definite MS and a navigator with probable MS. The various manifestations of MS are specifically addressed with an emphasis on the aeromedical implications.</description><subject>Adult</subject><subject>Aerospace Medicine</subject><subject>Executive Function</subject><subject>Humans</subject><subject>Israel</subject><subject>Male</subject><subject>Military Personnel</subject><subject>Multiple Sclerosis - complications</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Neurologic Examination</subject><subject>Optic Neuritis - drug therapy</subject><subject>Optic Neuritis - etiology</subject><subject>Paresthesia - drug therapy</subject><subject>Paresthesia - etiology</subject><subject>Space life sciences</subject><subject>Vision Disorders - drug therapy</subject><subject>Vision Disorders - etiology</subject><subject>Work Capacity Evaluation</subject><issn>0095-6562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtPwzAQhH0A0VK4ckS5cUpYP5LY3KpSHlIREo-z5bgbauQ0JXaE-PckauGyO4fZ0c5HyAWFjPO8vJ6_Lp8yVpYiY0DpEZkCqDwt8oJNyGkInwDABYMTMmGU8ZyCmpLbF4x9t01im9TefWxi8u3iJml6H93OYxKsx64NLtwkZhANrp01PrHtNrg1dia6QZ2R49r4gOeHPSPvd8u3xUO6er5_XMxXqWVCxZRKBRTBCKwqqdBIWJe2ssLIwnJVSFVUKDlTtDaspFahMApKQymX3ObDmJGrfe6ua796DFE3Llj03myx7YOWggtacOCDM9s77fB86LDWu841pvvRFPQIS4-w9AhLj7CGg8tDdF8NJf_tf6T4L8ctZuA</recordid><startdate>201101</startdate><enddate>201101</enddate><creator>Zinger, Hasya</creator><creator>Grossman, Alon</creator><creator>Assa, Amit</creator><creator>Barel, Oshri</creator><creator>Barenboim, Erez</creator><creator>Levite, Ronen</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201101</creationdate><title>Return to flight with multiple sclerosis: aeromedical considerations</title><author>Zinger, Hasya ; Grossman, Alon ; Assa, Amit ; Barel, Oshri ; Barenboim, Erez ; Levite, Ronen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c249t-18901e0a4ebb89ea80d7cbc4a86c396896be83291fa271c9e4a907a11383c5383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aerospace Medicine</topic><topic>Executive Function</topic><topic>Humans</topic><topic>Israel</topic><topic>Male</topic><topic>Military Personnel</topic><topic>Multiple Sclerosis - complications</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Neurologic Examination</topic><topic>Optic Neuritis - drug therapy</topic><topic>Optic Neuritis - etiology</topic><topic>Paresthesia - drug therapy</topic><topic>Paresthesia - etiology</topic><topic>Space life sciences</topic><topic>Vision Disorders - drug therapy</topic><topic>Vision Disorders - etiology</topic><topic>Work Capacity Evaluation</topic><toplevel>online_resources</toplevel><creatorcontrib>Zinger, Hasya</creatorcontrib><creatorcontrib>Grossman, Alon</creatorcontrib><creatorcontrib>Assa, Amit</creatorcontrib><creatorcontrib>Barel, Oshri</creatorcontrib><creatorcontrib>Barenboim, Erez</creatorcontrib><creatorcontrib>Levite, Ronen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Aviation, space, and environmental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zinger, Hasya</au><au>Grossman, Alon</au><au>Assa, Amit</au><au>Barel, Oshri</au><au>Barenboim, Erez</au><au>Levite, Ronen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Return to flight with multiple sclerosis: aeromedical considerations</atitle><jtitle>Aviation, space, and environmental medicine</jtitle><addtitle>Aviat Space Environ Med</addtitle><date>2011-01</date><risdate>2011</risdate><volume>82</volume><issue>1</issue><spage>61</spage><epage>64</epage><pages>61-64</pages><issn>0095-6562</issn><abstract>Multiple sclerosis (MS) is the most frequent demyelinating disease of the central nervous system, with versatile manifestations--relapsing-remitting or progressive--and an unpredictable course, with prognoses ranging from minimal neurological impairment to severely disabled. Disease modifying agents can minimize relapse rate and slow disease progression. Yet most patients suffer relapses and progression despite use of these agents. Several of the manifestations of MS may cause overall decrease in the performance of the aviator. These include cognitive impairment, fatigue, and depression. Episodes of spasms, dysarthria, ataxia, parasthesias, diplopia, and hemiplegia, as well as drug side effects may also affect flight. Seizures and episodes of vertigo may occur suddenly and result in in-flight incapacitation. We present our experience with two aviators with definite MS and a navigator with probable MS. The various manifestations of MS are specifically addressed with an emphasis on the aeromedical implications.</abstract><cop>United States</cop><pmid>21235109</pmid><doi>10.3357/ASEM.2774.2011</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0095-6562 |
ispartof | Aviation, space, and environmental medicine, 2011-01, Vol.82 (1), p.61-64 |
issn | 0095-6562 |
language | eng |
recordid | cdi_proquest_miscellaneous_843416303 |
source | MEDLINE; IngentaConnect Free/Open Access Journals |
subjects | Adult Aerospace Medicine Executive Function Humans Israel Male Military Personnel Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neurologic Examination Optic Neuritis - drug therapy Optic Neuritis - etiology Paresthesia - drug therapy Paresthesia - etiology Space life sciences Vision Disorders - drug therapy Vision Disorders - etiology Work Capacity Evaluation |
title | Return to flight with multiple sclerosis: aeromedical considerations |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A07%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Return%20to%20flight%20with%20multiple%20sclerosis:%20aeromedical%20considerations&rft.jtitle=Aviation,%20space,%20and%20environmental%20medicine&rft.au=Zinger,%20Hasya&rft.date=2011-01&rft.volume=82&rft.issue=1&rft.spage=61&rft.epage=64&rft.pages=61-64&rft.issn=0095-6562&rft_id=info:doi/10.3357/ASEM.2774.2011&rft_dat=%3Cproquest_cross%3E843416303%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=843416303&rft_id=info:pmid/21235109&rfr_iscdi=true |